Fedratinib Pill

DRUG2 trials

Sponsors

H. Lee Moffitt Cancer Center and Research Institute

Conditions

Chronic Neutrophilic LeukemiaMDSMyeloproliferative Neoplasm

Phase 1

Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms

TerminatedNCT05127174

H. Lee Moffitt Cancer Center and Research InstituteMyeloproliferative Neoplasm

Start: 2022-03-14End: 2025-01-03Updated: 2025-12-04

Phase 2

Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)

CompletedNCT05177211

H. Lee Moffitt Cancer Center and Research InstituteChronic Neutrophilic Leukemia, MDS, Myeloproliferative Neoplasm

Start: 2022-03-01End: 2026-01-09Updated: 2026-06-09

Related Papers

A Phase 2 Study of Fedratinib in Patients with MDS/MPN and Chronic Neutrophilic Leukemia

Blood2024-11-055 citations

A Phase 2 Study of Fedratinib in Patients with MDS/MPN and Chronic Neutrophilic Leukemia

Blood2023-11-027 citations